European Commissioner Joaquin Almunia has reportedly confirmed that he is “gathering information” regarding allegations that pharmaceutical giants Roche Holding and Novartis colluded to prevent the sale of an eye disease treatment in favor of selling the treatment’s more expensive counterpart.
Almunia answered reporter questions Monday and confirmed that the Commission would “assess whether further action is needed” regarding the matter, but declined to elaborate. A formal investigation has not been opened.
Italian regulators fined the companies more than $254 million in 2012 for similar allegations. Italy’ antitrust regulator sanctioned the firms after finding that the companies colluded to block eye disease medicine Avastin so a more expensive drug, Lucentis, could be sold. The companies jointly market for Lucentis.
Novartis is appealing Italy’s decision.
Almunia told reporters, however, that the case in Italy will not impact the Commission’s actions on the matter, and does not necessarily indicate similar anticompetitive conduct by the companies in other EU member states.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Equifax Must Face Suit Over Alleged Market Monopolization
Feb 19, 2025 by
CPI
Public Interest Groups Push for Rehearing on FCC Net Neutrality Case
Feb 18, 2025 by
CPI
Australian Regulator Backs Virgin Australia-Qatar Airways Alliance
Feb 18, 2025 by
CPI
EU Scales Back AI Regulations to Compete with US in Global Tech Race
Feb 18, 2025 by
CPI
Democratic Lawmakers Raise Concerns Over Musk’s Task Force and Taxpayer Data Security
Feb 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon